|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
4
|
|
pubmed:dateCreated |
2011-6-13
|
|
pubmed:abstractText |
Recent developments in multi-functional nanoparticles offer a great potential for targeted delivery of therapeutic compounds and imaging contrast agents to specific cell types, in turn, enhancing therapeutic effect and minimizing side effects. Despite the promise, site specific delivery carriers have not been translated into clinical reality. In this study, we have developed long circulating liposomes with the outer surface decorated with thioated oligonucleotide aptamer (thioaptamer) against E-selectin (ESTA) and evaluated the targeting efficacy and PK parameters. In vitro targeting studies using Human Umbilical Cord Vein Endothelial Cell (HUVEC) demonstrated efficient and rapid uptake of the ESTA conjugated liposomes (ESTA-lip). In vivo, the intravenous administration of ESTA-lip resulted in their accumulation at the tumor vasculature of breast tumor xenografts without shortening the circulation half-life. The study presented here represents an exemplary use of thioaptamer and liposome and opens the door to testing various combinations of thioaptamer and nanocarriers that can be constructed to target multiple cancer types and tumor components for delivery of both therapeutics and imaging agent.
|
|
pubmed:grant |
|
|
pubmed:commentsCorrections |
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Apr
|
|
pubmed:issn |
1949-2553
|
|
pubmed:author |
pubmed-author:AnnapragadaAnanthA,
pubmed-author:BhavaneRohan CRC,
pubmed-author:FerrariMauroM,
pubmed-author:GhaghadaKetan BKB,
pubmed-author:GorensteinDavid GDG,
pubmed-author:Liz Montalvo-OrtizBrendaB,
pubmed-author:MannAman PAP,
pubmed-author:Nieves-AliceaRenéR,
pubmed-author:SomasunderamAnomaA,
pubmed-author:SuhK StephenKS,
pubmed-author:VolkDavidD,
pubmed-author:ZelTT
|
|
pubmed:issnType |
Electronic
|
|
pubmed:volume |
2
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
298-304
|
|
pubmed:meshHeading |
pubmed-meshheading:21666286-Angiogenesis Inhibitors,
pubmed-meshheading:21666286-Animals,
pubmed-meshheading:21666286-Antineoplastic Agents,
pubmed-meshheading:21666286-Aptamers, Nucleotide,
pubmed-meshheading:21666286-Breast Neoplasms,
pubmed-meshheading:21666286-Carcinoma,
pubmed-meshheading:21666286-Cells, Cultured,
pubmed-meshheading:21666286-Drug Carriers,
pubmed-meshheading:21666286-Drug Delivery Systems,
pubmed-meshheading:21666286-Endothelial Cells,
pubmed-meshheading:21666286-Female,
pubmed-meshheading:21666286-Humans,
pubmed-meshheading:21666286-Liposomes,
pubmed-meshheading:21666286-Mice,
pubmed-meshheading:21666286-Mice, Nude,
pubmed-meshheading:21666286-Models, Biological,
pubmed-meshheading:21666286-Neoplasms,
pubmed-meshheading:21666286-Neovascularization, Pathologic,
pubmed-meshheading:21666286-Sulfhydryl Compounds,
pubmed-meshheading:21666286-Xenograft Model Antitumor Assays
|
|
pubmed:year |
2011
|
|
pubmed:articleTitle |
Thioaptamer conjugated liposomes for tumor vasculature targeting.
|
|
pubmed:affiliation |
Department of Nanomedicine, University of Texas Health Science Center at Houston, 1825 Hermann Pressler, Houston, Texas 77030, USA.
|
|
pubmed:publicationType |
Journal Article,
Research Support, U.S. Gov't, Non-P.H.S.,
Research Support, Non-U.S. Gov't,
Research Support, N.I.H., Extramural
|
